新辅助化疗治疗晚期子宫内膜癌的临床疗效及并发症分析

发布时间：2018-06-02 18:11

本文选题：新辅助化疗 + 晚期子宫内膜癌　；参考：《中国妇产科临床杂志》2017年05期

【摘要】：目的分析新辅助化疗治疗晚期子宫内膜癌疗效。方法收集2012年2月至2013年6月新疆医科大学附属肿瘤医院收治的子宫内膜癌患者74例,随机分为对照组、观察组各37例;对照组采用常规手术治疗,术后辅助放化疗、激素治疗,观察组联合术前辅助化疗。结果新辅助化疗完全缓解2.7%、部分缓解54.1%、稳定40.5%、进展2.7%,缓解56.8%,控制97.3%;观察组术中出血量、手术时间低于对照组,观察组无瘤生存时间(24.4±5.6)个月,高于对照组(20.3±5.1)个月,对照组总有效率54.04%低于观察组75.68%,差异有统计学意义(P0.05);观察组、对照组生活质量术后明显下降,差异有统计学意义,(P0.05);两组之间治疗前、化疗后、手术后生活质量比较差异无统计学意义(P0.05)。结论新辅助化疗治疗晚期子宫内膜癌可增进近期疗效,但可能导致肿瘤进展。
[Abstract]:Objective to analyze the efficacy of neoadjuvant chemotherapy in the treatment of advanced endometrial carcinoma. Methods from February 2012 to June 2013, 74 patients with endometrial carcinoma were randomly divided into control group (n = 37) and control group (n = 37). Hormone therapy, observation group combined with preoperative adjuvant chemotherapy. Results Neoadjuvant chemotherapy completely alleviated 2.7g, partially relieved 54.1, stabilized 40.5, progressed 2.7, alleviated 56.8 and controlled 97.3.The blood loss during operation in the observation group was lower than that in the control group, and the survival time of the observation group was 24.4 卤5.6 months, which was higher than that of the control group (20.3 卤5.1) months. The total effective rate of the control group was 54.04% lower than that of the observation group (75.68%), the difference was statistically significant (P 0.05), while in the observation group, the quality of life in the control group decreased significantly after operation, and the difference was statistically significant (P 0.05). There was no significant difference in quality of life after operation (P 0.05). Conclusion Neoadjuvant chemotherapy for advanced endometrial carcinoma may enhance the short-term efficacy, but may lead to tumor progression.
【作者单位】：新疆医科大学附属肿瘤医院妇外一科;
【分类号】：R737.33

【相似文献】